Nilotinib Stada 150 Mg Tvrdé Tobolky (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling pathways that promote proliferation and survival of leukemic cells. The drug also inhibits related kinases such as KIT and PDGFR, contributing to its antineoplastic effect in Philadelphia chromosome‑positive CML.

The specific dose of nilotinib is determined by the prescribing physician based on the patient’s clinical condition, prior therapies, and tolerability. Dosing recommendations are provided in the product’s prescribing information, and adjustments may be required for factors such as liver function, drug interactions, or adverse events.

The safety of nilotinib during pregnancy or while breastfeeding has not been established. It is classified as contraindicated for use in pregnant women unless the potential benefit justifies the risk to the fetus. Women of child‑bearing potential should use effective contraception, and nursing mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency and selectivity compared with first‑generation agents such as imatinib. Clinical studies have shown faster and deeper molecular responses in many patients, especially those who are resistant or intolerant to imatinib. However, nilotinib carries a distinct safety profile, including a higher risk of QT prolongation, which must be considered when selecting therapy.

Store the tablets at below 25 °C (77 °F) in their original container, protecting them from moisture, heat and direct sunlight. Keep the packaging tightly closed and avoid exposure to humidity. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Nilotinib is taken orally, usually as whole tablets swallowed with a moderate‑fat meal to improve absorption. The medication should be taken at the same times each day, and patients are advised not to crush, split, or chew the tablets. Water is the preferred fluid for ingestion, and dosing intervals should be maintained consistently.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias; severe hepatic toxicity; pancreatitis; and profound neutropenia or thrombocytopenia that increase infection or bleeding risk. Patients should be monitored regularly with ECGs, liver function tests, pancreatic enzymes, and complete blood counts to detect these events early.

Nilotinib should not be used by patients with a known hypersensitivity to the drug or any of its excipients. It is also contraindicated in individuals with a history of significant QT prolongation, uncontrolled cardiac arrhythmias, or severe hepatic impairment. Clinicians must evaluate each patient’s medical history before initiating therapy.